Skylark Pharmaceuticals Private Limited, a active private limited company, was established on 18 July 2005 in Ankleshwar, Gujarat, India. Engaging in drug formulation & development within the manufacturing sector, it holds CIN: U24230GJ2005PTC046440. Registered under ROC Roc Ahmedabad. it is unlisted. It has an authorized capital of ₹7.00 Cr and a paid-up capital of ₹1.00 Cr.
It upholds a compliant status. Employing 6 professional, Its leadership includes Kamleshkumar Gaurishankar Patel (Director), Mukesh Narbheram Chadderwala (Director), Prakashbhai Narbhaeram Chadderwala (Director). Past directors included Kapilaben Narbheram Chadderwala, Prakashbhai Narbhaeram Chadderwala. It holds no open charges and ₹10.50 Cr settled loans. Its latest AGM occurred on 30 September 2024, with the balance sheet filed on 31 March 2024. It is based at Plot No. 7910 Gidc Ankleshwar, Ankleshwar, Gujarat, 393002.
U24230GJ2005PTC046440
046440
18 July 2005
₹7.00 Cr
₹1.00 Cr
Roc Ahmedabad
Unlisted
Active
Explore comprehensive insights into Skylark Pharmaceuticals Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Kamleshkumar Gaurishankar Patel | Director | 18 Jul 2005 | Current |
| Mukesh Narbheram Chadderwala | Director | 18 Jul 2005 | Current |
| Prakashbhai Narbhaeram Chadderwala | Director | 11 Apr 2013 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Director | 15 May 2009 | Past |
| Pramod Abcsdd | Additional Director | 30 Sep 2013 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Skylark Pharmaceuticals Private Limited, for the financial year ended 2024, experienced significant reduction in revenue, with a 40.32% decrease. The company also saw a substantial fall in profitability, with a 11.33% decrease in profit. The company's net worth observed a substantial decline by a decrease of 12.91%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
Unlock access to Skylark Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Reveal ownership structures and financial performance - Get instant access now!
₹0
₹105,000,000.00
| Date | Lender | Amount | Status |
|---|---|---|---|
| 29 Oct 2020 | Others | ₹1.00 Cr | Satisfied |
| 04 Jun 2016 | Others | ₹1.50 Cr | Satisfied |
| 19 Feb 2014 | Prime Co-Operative Bank Limited | ₹5.50 Cr | Satisfied |
| 01 Jan 2014 | Prime Co-Operative Bank Limited | ₹2.50 Cr | Satisfied |
Explore comprehensive loan charge details -
Skylark Pharmaceuticals has a workforce of 6 employees as of Mar 26, 2025. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Gain comprehensive insights into the Deals and Valuation data of Skylark Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Skylark Pharmaceuticals's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
The activity A charge registered on 29 Oct 2020 via Charge ID 100387720 with Others was fully satisfied on 25 Nov 2024. was completed.
A charge registered on 04 Jun 2016 via Charge ID 100034244 with Others was fully satisfied on 25 Nov 2024. was recorded as a recent event.
Progress on A charge registered on 19 Feb 2014 via Charge ID 10480639 with Prime Co-Operative Bank Limited was fully satisfied on 25 Nov 2024. was documented.
A charge registered on 01 Jan 2014 via Charge ID 10473923 with Prime Co-Operative Bank Limited was fully satisfied on 25 Nov 2024. was recorded as a recent event.
The activity Skylark Pharmaceuticals Private Limited last Annual general meeting of members was held on 30 Sep 2024 as per latest MCA records. was completed.
Progress on Skylark Pharmaceuticals Private Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Ahmedabad. was documented.
The CIN of Skylark Pharmaceuticals Private Limited is U24230GJ2005PTC046440.
Skylark Pharmaceuticals Private Limited is headquartered at Plot No. 7910 Gidc Ankleshwar, Ankleshwar, Gujarat, 393002.
Skylark Pharmaceuticals Private Limited was incorporated on 18 July 2005.
The current directors of Skylark Pharmaceuticals Private Limited are
The primary industry of Skylark Pharmaceuticals Private Limited is Manufacturing.
Skylark Pharmaceuticals Private Limited is unlisted.
The authorized capital of Skylark Pharmaceuticals Private Limited is ₹7.00 Cr, and the paid-up capital is ₹1.00 Cr.
The compliance status of Skylark Pharmaceuticals Private Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX